Exodus Point Capital Management, LP Viridian Therapeutics, Inc.\De Transaction History

Exodus Point Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$15.16 - $24.7 $494,064 - $804,973	-32,590 Reduced 15.73%	174,621 $2.68 Million
Q2 2023 Aug 10, 2023	BUY	$22.57 - $29.67 $1.81 Million - $2.38 Million	80,310 Added 63.29%	207,211 $4.93 Million
Q1 2023 May 11, 2023	SELL	$25.04 - $37.6 $1.6 Million - $2.4 Million	-63,753 Reduced 33.44%	126,901 $3.23 Million
Q4 2022 Feb 13, 2023	BUY	$18.78 - $29.74 $1.53 Million - $2.43 Million	81,686 Added 74.96%	190,654 $5.57 Million
Q3 2022 Nov 10, 2022	BUY	$10.7 - $25.5 $1.17 Million - $2.78 Million	108,968 New	108,968 $2.24 Million
Q2 2022 Aug 19, 2022	SELL	$9.55 - $19.0 $933,464 - $1.86 Million	-97,745 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$16.79 - $20.88 $352,388 - $438,229	20,988 Added 27.34%	97,745 $1.81 Million
Q4 2021 Feb 11, 2022	BUY	$15.65 - $21.5 $1.2 Million - $1.65 Million	76,757 New	76,757 $1.52 Million

179

76.8M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $859M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.